Patiromer sorbitex calcium Drug Due Diligence Report 2026

This Patiromer sorbitex calcium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Patiromer sorbitex calcium can convert its Small molecule drug profile and Potassium biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Patiromer sorbitex calcium (query alias: patiromer)
Modality / target	Small molecule drug; Potassium; Potassium modulators
Highest global status	Approved
Originator	Corden Pharma Fribourg SA
Active developers	Corden Pharma Fribourg SA, Vifor Fresenius Medical Care Renal Pharma France, Zeria Pharmaceutical Co., Ltd.

The MCP disease footprint includes Hyperkalemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06256991	Phase 4	Recruiting	44	Albumin-creatinine ratio (ACR)
NCT06858280	Phase 3	Recruiting	40	Serum potassium levels
LBCTR2023055223	Phase 2	Other	21	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Comparison of Potassium Binders in the ER

Phase 4; n=37; evaluation: not stated. Reported fields: -; 2 hours(Mean) = -0.69 mEq/L (Standard Deviation, 0.40); -

Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department

Phase 2; n=111; evaluation: Negative. Reported fields: NCB: P-Value = 0.44; NCB: P-Value = 0.44

A Phase IV, Registry-based, Randomised, Controlled, Open-label Trial Investigating the Potential for Patiromer-facilitated Use of Higher Doses of MRAs in Addition to Standard Care to Improve Congestion, Well-being, Morbidity and Mortality

Phase 4; n=19; evaluation: not stated. Reported fields: -; -; Other (Not Including Serious) Adverse Events = 0 Participants

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Patiromer sorbitex calcium addresses Hyperkalemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-11-19	VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement	Approved	Financial terms not disclosed
2013-08-19	Vifor and Zeria sign deal for Ferinject in Japan	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Potassium-binding agents for treating hypertension and hyperkalemia”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO